Objective: To explore the correlation between the composition of bone marrow lymphocyte subsets and the clinical attributes observed in de novo AML patients, as well as their influence on prognosis. Methods: A detailed study was carried out on a cohort of 191 de novo acute myeloid leukemia patients who were admitted to our medical center between October 2022 and September 2024. In addition, a group of 24 patients with iron deficiency anemia individuals was carefully chosen as the control cohort. The proportions of lymphocyte subsets within the bone marrow of de novo AML patients were analyzed. Furthermore, an in-depth analysis was performed to investigate the association between the expression levels of these subsets in de novo AML patients and their clinical attributes, as well as their prognostic implications. Results: The proportion of CD19 and CD56 lymphocytes within the bone marrow of de novo AML patients significantly diminished compared to the control cohort (8.5% vs 13.2% P<0.05, and 15.5% vs 18.0%, P<0.05). Conversely, no significant discrepancies were observed in the CD3 , CD3 CD4 , and CD3 CD8 lymphocyte percentages between the AML patients and control group (71.7% vs 72.1%, 32.5% vs 33.7% and 32.8% vs 35.7%, P>0.05). When analyzing the relationships between lymphocyte subsets within the bone marrow of de novo patients and their respective clinical characteristics, patients aged 60 years and above exhibited diminished percentages of CD3 CD8 lymphocytes in the bone marrow compared to their younger counterparts (31.6% vs 34.1%, P<0.05), while the CD56 lymphocyte subsets demonstrated an increased prevalence (17.2% vs 14.4%, P<0.05). Furthermore, patients with leukocytosis (WBC≥100×10 /L) presented lower levels of CD3 and CD3 CD4 lymphocytes in the bone marrow compared with those without it (65.3% vs 72.9% P<0.05, and 28.9% vs 33.2%, P<0.05), respectively. The AML1-ETO fusion gene-positive cohort exhibited a higher prevalence of CD3 CD8 lymphocytes in the bone marrow than in the negative group (38.2% vs 32.3%, P<0.05), whereas the FLT3-ITD mutation-positive group presented a decreased prevalence of CD56 lymphocytes compared with the negative group (12.4% vs 16.8%, P<0.05). In addition, the NPM1 mutation-positive group demonstrated lower levels of CD3 CD8 lymphocytes in the bone marrow than in the negative group (29.1% vs 33.3%, P<0.05). Variables such as tumor protein p53(TP53) mutation positive, the absence of hematopoietic stem cell transplantation, and CD3 CD4 lymphocyte proportions below 25% were identified as independent adverse prognostic indicators for AML patients (P<0.05). Conclusion: The pathogenesis of AML is closely associated with an imbalance in bone marrow lymphocyte subsets. The FLT3-ITD mutation potentially contributes to the dysregulation of CD56 lymphocyte subset expression. The AML1-ETO fusion gene and NPM1 mutation are implicated in the abnormal expression of CD3 CD8 lymphocytes within the bone marrow. Moreover, the percentage of CD3 CD4 lymphocytes in the bone marrow serves as a prognostic factor for de novo AML patients.

Objective To explore the prognosis related influencing factors of immunotherapy in the pa-tients with advanced non-small cell lung cancer(NSCLC)to provide reference for clinical treatment and prog-nosis evaluation of the patients.Methods The clinical data of 132 patients with advanced NSCLC receiving the immunotherapy admitted and treated in the Anqing Medical Center of Anhui Medical University from Oc-tober 2019 to June 2022 were retrospectively analyzed.The overall survival(OS)and progression-free survival(PFS)of the patients were statistically analyzed.The Cox univariate and multivariate models were used to an-alyze the prognosis related influencing factors.Results The median OS time in 132 cases was 20.10 months and the median PFS time was 14.95 months.The results of multi-factor analysis showed that the ECOG score,number of treatment lines and receiving palliative radiotherapy were the independent influencing factors of OS time in the patients with advanced NSCLC(P<0.05).Hemoglobin,C-reactive protein(CRP),ECOG score and number of treatment lines were the independent risk factors of PFS time in the patients with ad-vanced NSCLC(P<0.05).Conclusion The patients with hemoglobin≥110 g/L,CRP<6 mg/L,ECOG score 0-1 point,first line immunotherapy,receiving palliative radiotherapy could obtain the benefit from immunotherapy.

OBJECTIVES: To investigate the mechanism underlying the inhibitory effect of Buyang Huanwu Decoction (BYHWD) on vascular aging. METHODS: Eighteen male SD rats were randomized into young group, intraperitoneal D-galactose injection-induced aging group, and BYHWD gavage group. The changes in pulse wave velocity (PWV), vascular SA-β-gal activity, and expressions of p16, p21 and SA‑β‑gal of the rats were examined. Serum exosomes were isolated from the rats, and after characterization using NTA and TEM and for surface markers and vascular cell markers, were examined for miR-590-5p expression using qRT-PCR. The M1/M2 macrophage ratio and cytokine levels were evaluated using immunofluorescence staining and qRT-PCR. Bioinformatics analysis and dual-luciferase reporter assays were carried out to predict the potential target genes of miR-590-5p and validate its targeting relationship with SLC8A3, whose expressions were detected in the vascular tissues of the rats by Western blotting. RESULTS: Compared with the young rats, the aging rats exhibited significantly increased PWV in the abdominal aorta with elevated vascular expressions of p16, p21 and SA-β-gal, which were all reversed by BYHWD treatment. The isolated serum exosomes were positive for CD63, CD81, CD31 and SM-22, and the exosomes from aging rats showed significantly downregulated expression of miR-590-5p, which was upregulated after BYHWD treatment. The aging rat vessels showed an increased M1/M2 macrophage ratio with elevated M1-specific cytokines and reduced M2-specific cytokines, and BYHWD treatment effectively inhibited M1 polarization of the macrophages. Pearson analysis revealed a negative correlation between exosomal miR-590-5p upregulation and the M1/M2 ratio. Bioinformatics analysis and dual-luciferase assays confirmed that miR-590-5p targets SLC8A3. Western blotting demonstrated increased SLC8A3 expression in aging rat vessels, which was downregulated after BYHWD treatment. CONCLUSIONS BYHWD attenuates vascular aging in rats by modulating macrophage M1 polarization and suppressing vascular inflammation via exosomal miR-590-5p-mediated downregulation of SLC8A3.
Animals ; MicroRNAs/genetics* ; Rats, Sprague-Dawley ; Drugs, Chinese Herbal/pharmacology* ; Male ; Macrophages/drug effects* ; Rats ; Exosomes/metabolism* ; Aging/drug effects* ; Signal Transduction

Objective To investigate the impact of sintilimab combined with TP chemotherapy regimen on immune function and prognostic survival in patients with advanced esophageal cancer.Methods A total of 82 patients with advanced esophageal cancer who received treatment in the hospital from January 2022 to October 2023 were enrolled.They were divided into two groups with 41 cases in each group using the random number table method.The control group was given the TP chemotherapy regimen,while the observation group was treated with sintilimab in addition to the TP chemotherapy regimen used in the control group.The treatment cycle was 21 days,and both groups received 4 cycles of treatment.After that,the observation group received sintilimab monotherapy for maintenance treatment for at least 1 year.The disease control rate(DCR)and objective response rate(ORR)of the patients were recorded.The immune function,levels of inflammatory factors and tumor markers before and after treatment were compared between the two groups.The swallowing function and quality of life of the patients before and after treatment were evaluated using the Swallowing Safety Assessment(SSA)and the Quality of Life Instruments for Cancer Patients-Esophageal Cancer(QLICP-ES).The occurrence of adverse reactions was also recorded.After the start of treatment,the patients were followed up for 18 months,and the overall survival(OS)and survival rate were recorded.Results In the observation group,the partial remission rate and disease control rate were 53.66%and 87.80%respectively,both higher than those in the control group.After treatment,the levels of CD3+and CD4+in the observation group were(50.48±5.61)%and(37.96±4.69)%respectively,which were higher than(44.73±5.12)%and(33.15±4.21)%in the control group.The immune function of the observation group was improved compared with the control group,while the levels of inflammatory factors and tumor markers were lower than those in the control group.The swallowing function and quality of life were significantly improved compared with the control group(P<0.05).The 18-month follow-up results showed that the median overall survival(OS)in the observation group was 16(9,17)months,and that in the control group was 9(7,14)months.The OS in the observation group was longer than that in the control group(χ2=13.394,P<0.001).The 18months survival rates in the observation group and the control group were 60.98%(25/41)and 36.59%(15/41)respec-tively,with the observation group being higher than the control group(χ2=4.881,P=0.027).Conclusion The sintilimab combined with TP chemotherapy regimen is beneficial for improving immune function and enhancing the survival status of patients with advanced esophageal cancer.

Objective:To explore the clinicopathologic features differences between tall cell variant of papillary thyroid cancer (TCV-PTC) and PTC with tall cell features (PTC-TCF) and the factors influencing efficacy of 131I therapy in patients with TCV-PTC and PTC-TCF. Methods:A retrospective analysis was conducted on 84 patients (28 males, 56 females, age 43.5(35.0, 55.0) years) with pathologically confirmed TCV-PTC or PTC-TCF and who were treated with 131I therapy from January 2018 to June 2023 in the Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University. The patients were divided into structural incomplete response (SIR) group and non-SIR group according to 131I treatment response. Data differences were analyzed by Wilcoxon rank sum test, Fisher exact test, or Mann-Whitney U test. Variables with P<0.1 were enrolled in logistic multivariate regression analysis. The ROC curve was used to obtain the cut-off value of stimulated thyroglobulin (sTg). Results:A total of 37 patients with non-SIR and 6 patients with SIR were found in TCV-PTC group ( n=43), and 33 non-SIR and 8 SIR cases were found in PTC-TCF group ( n=41). Univariate analysis revealed that sTg differed significantly between non-SIR patients and SIR patients in TCV-PTC group ( Z=-2.81, P=0.003), while no significant differences observed for sex, age, multifocality, capsular invasion, T stage, N stage, B-Raf proto-oncogene, serine/threonine-protein kinase (BRAF) V600E mutation, initial recurrence risk, number of metastatic lymph nodes, maximum tumor diameter ( Z values: from -0.74 to -0.11, all P>0.05). In TCV-PTC group, sTg also differed significantly between non-SIR patients and SIR patients ( Z=-4.40, P<0.001), while the other clinical factors above and the proportion of tall cells showed no significant difference ( Z values: from -1.90 to -0.22, all P>0.05). The logistic regression analysis confirmed sTg as an independent risk factor of SIR in both TCV-PTC group (odds ratio ( OR) = 25.156, 95% CI: 2.245-281.812, P=0.009) and PTC-TCF group ( OR=19.214, 95% CI: 2.537-145.502, P=0.004). The ROC curve indicated that the cut-off value of sTg for predicting SIR was 20.75μg/L in TCV-PTC group and 18.55μg/L in PTC-TCF group. Conclusions:sTg is the independent risk factor for predicting the poor prognosis of patients with TCV-PTC (sTg≥20.75μg/L) and PTC-TCF (sTg≥18.55μg/L). However, other clinical characteristics show no statistical difference between TCV-PTC group and PTC-TCF group, suggesting that the invasiveness of PTC-TCF may not be lower than that of TCV-PTC, which close attention should be paid to in clinical practice.

Objective To investigate the mechanism underlying the inhibitory effect of Buyang Huanwu Decoction(BYHWD)on vascular aging.Methods Eighteen male SD rats were randomized into young group,intraperitoneal D-galactose injection-induced aging group,and BYHWD gavage group.The changes in pulse wave velocity(PWV),vascular SA-β-gal activity,and expressions of p16,p21 and SA-β-gal of the rats were examined.Serum exosomes were isolated from the rats,and after characterization using NTA and TEM and for surface markers and vascular cell markers,were examined for miR-590-5p expression using qRT-PCR.The M1/M2 macrophage ratio and cytokine levels were evaluated using immunofluorescence staining and qRT-PCR.Bioinformatics analysis and dual-luciferase reporter assays were carried out to predict the potential target genes of miR-590-5p and validate its targeting relationship with SLC8A3,whose expressions were detected in the vascular tissues of the rats by Western blotting.Results Compared with the young rats,the aging rats exhibited significantly increased PWV in the abdominal aorta with elevated vascular expressions of p16,p21 and SA-β-gal,which were all reversed by BYHWD treatment.The isolated serum exosomes were positive for CD63,CD81,CD31 and SM-22,and the exosomes from aging rats showed significantly downregulated expression of miR-590-5p,which was upregulated after BYHWD treatment.The aging rat vessels showed an increased M1/M2 macrophage ratio with elevated M1-specific cytokines and reduced M2-specific cytokines,and BYHWD treatment effectively inhibited M1 polarization of the macrophages.Pearson analysis revealed a negative correlation between exosomal miR-590-5p upregulation and the M1/M2 ratio.Bioinformatics analysis and dual-luciferase assays confirmed that miR-590-5p targets SLC8A3.Western blotting demonstrated increased SLC8A3 expression in aging rat vessels,which was downregulated after BYHWD treatment.Conclusion BYHWD attenuates vascular aging in rats by modulating macrophage M1 polarization and suppressing vascular inflammation via exosomal miR-590-5p-mediated downregulation of SLC8A3.

Objective: To explore the correlation between the composition of bone marrow lymphocyte subsets and the clinical attributes observed in de novo AML patients, as well as their influence on prognosis. Methods: A detailed study was carried out on a cohort of 191 de novo acute myeloid leukemia patients who were admitted to our medical center between October 2022 and September 2024. In addition, a group of 24 patients with iron deficiency anemia individuals was carefully chosen as the control cohort. The proportions of lymphocyte subsets within the bone marrow of de novo AML patients were analyzed. Furthermore, an in-depth analysis was performed to investigate the association between the expression levels of these subsets in de novo AML patients and their clinical attributes, as well as their prognostic implications. Results: The proportion of CD19 and CD56 lymphocytes within the bone marrow of de novo AML patients significantly diminished compared to the control cohort (8.5% vs 13.2% P<0.05, and 15.5% vs 18.0%, P<0.05). Conversely, no significant discrepancies were observed in the CD3 , CD3 CD4 , and CD3 CD8 lymphocyte percentages between the AML patients and control group (71.7% vs 72.1%, 32.5% vs 33.7% and 32.8% vs 35.7%, P>0.05). When analyzing the relationships between lymphocyte subsets within the bone marrow of de novo patients and their respective clinical characteristics, patients aged 60 years and above exhibited diminished percentages of CD3 CD8 lymphocytes in the bone marrow compared to their younger counterparts (31.6% vs 34.1%, P<0.05), while the CD56 lymphocyte subsets demonstrated an increased prevalence (17.2% vs 14.4%, P<0.05). Furthermore, patients with leukocytosis (WBC≥100×10 /L) presented lower levels of CD3 and CD3 CD4 lymphocytes in the bone marrow compared with those without it (65.3% vs 72.9% P<0.05, and 28.9% vs 33.2%, P<0.05), respectively. The AML1-ETO fusion gene-positive cohort exhibited a higher prevalence of CD3 CD8 lymphocytes in the bone marrow than in the negative group (38.2% vs 32.3%, P<0.05), whereas the FLT3-ITD mutation-positive group presented a decreased prevalence of CD56 lymphocytes compared with the negative group (12.4% vs 16.8%, P<0.05). In addition, the NPM1 mutation-positive group demonstrated lower levels of CD3 CD8 lymphocytes in the bone marrow than in the negative group (29.1% vs 33.3%, P<0.05). Variables such as tumor protein p53(TP53) mutation positive, the absence of hematopoietic stem cell transplantation, and CD3 CD4 lymphocyte proportions below 25% were identified as independent adverse prognostic indicators for AML patients (P<0.05). Conclusion: The pathogenesis of AML is closely associated with an imbalance in bone marrow lymphocyte subsets. The FLT3-ITD mutation potentially contributes to the dysregulation of CD56 lymphocyte subset expression. The AML1-ETO fusion gene and NPM1 mutation are implicated in the abnormal expression of CD3 CD8 lymphocytes within the bone marrow. Moreover, the percentage of CD3 CD4 lymphocytes in the bone marrow serves as a prognostic factor for de novo AML patients.

Objective To analyze the characteristics of the crown-root ratios of the anterior teeth in subjects with different periodontal phenotypes in healthy population.Methods A total of 100 periodontally healthy young volunteers were selected,there were 53 females and 47 males,totaling 594 anterior teeth were included in the study.The periodontal probe method was used to determine the periodontal phenotypes of different tooth positions,with 108 cases of thick gingival type and 90 cases of thin gingival type in mesial incisors;95 teeth of thick gingival type and 103 teeth of thin gingival type in lateral incisors,and 98 teeth of thick gingival type and 100 teeth of thin gingival type in cuspids.Panoramic radiographs were taken,crown length and root length of upper anterior teeth were calculated,and crown-root ratio was calculated,to compare and analyze the differences between the results of the two groups.Results The crown-to-root ratio in thin gingival group of mesial incisors and lateral incisors were higher than those in thick gingival group,and the root length was smaller than thick gingival group.The difference was statistically significant(P＜0.05).The keratinized gingival width of thin gingival group was less than that of thick gingival group,and the difference was statistically significant(P＜0.05).Conclusion The relatively high crown-to-root ratio of mesial incisors and lateral incisors in patients with thin gingival phenotypes and the lesser width of keratinized gingiva in thin gingival phenotypes than thick gingival phenotypes.and risk assessment should be taken into account in the restorative system as well as in the orthodontic design of the anterior tooth movement.

Objective To investigate the impact of sintilimab combined with TP chemotherapy regimen on immune function and prognostic survival in patients with advanced esophageal cancer.Methods A total of 82 patients with advanced esophageal cancer who received treatment in the hospital from January 2022 to October 2023 were enrolled.They were divided into two groups with 41 cases in each group using the random number table method.The control group was given the TP chemotherapy regimen,while the observation group was treated with sintilimab in addition to the TP chemotherapy regimen used in the control group.The treatment cycle was 21 days,and both groups received 4 cycles of treatment.After that,the observation group received sintilimab monotherapy for maintenance treatment for at least 1 year.The disease control rate(DCR)and objective response rate(ORR)of the patients were recorded.The immune function,levels of inflammatory factors and tumor markers before and after treatment were compared between the two groups.The swallowing function and quality of life of the patients before and after treatment were evaluated using the Swallowing Safety Assessment(SSA)and the Quality of Life Instruments for Cancer Patients-Esophageal Cancer(QLICP-ES).The occurrence of adverse reactions was also recorded.After the start of treatment,the patients were followed up for 18 months,and the overall survival(OS)and survival rate were recorded.Results In the observation group,the partial remission rate and disease control rate were 53.66%and 87.80%respectively,both higher than those in the control group.After treatment,the levels of CD3+and CD4+in the observation group were(50.48±5.61)%and(37.96±4.69)%respectively,which were higher than(44.73±5.12)%and(33.15±4.21)%in the control group.The immune function of the observation group was improved compared with the control group,while the levels of inflammatory factors and tumor markers were lower than those in the control group.The swallowing function and quality of life were significantly improved compared with the control group(P<0.05).The 18-month follow-up results showed that the median overall survival(OS)in the observation group was 16(9,17)months,and that in the control group was 9(7,14)months.The OS in the observation group was longer than that in the control group(χ2=13.394,P<0.001).The 18months survival rates in the observation group and the control group were 60.98%(25/41)and 36.59%(15/41)respec-tively,with the observation group being higher than the control group(χ2=4.881,P=0.027).Conclusion The sintilimab combined with TP chemotherapy regimen is beneficial for improving immune function and enhancing the survival status of patients with advanced esophageal cancer.

Objective To analyze the characteristics of the crown-root ratios of the anterior teeth in subjects with different periodontal phenotypes in healthy population.Methods A total of 100 periodontally healthy young volunteers were selected,there were 53 females and 47 males,totaling 594 anterior teeth were included in the study.The periodontal probe method was used to determine the periodontal phenotypes of different tooth positions,with 108 cases of thick gingival type and 90 cases of thin gingival type in mesial incisors;95 teeth of thick gingival type and 103 teeth of thin gingival type in lateral incisors,and 98 teeth of thick gingival type and 100 teeth of thin gingival type in cuspids.Panoramic radiographs were taken,crown length and root length of upper anterior teeth were calculated,and crown-root ratio was calculated,to compare and analyze the differences between the results of the two groups.Results The crown-to-root ratio in thin gingival group of mesial incisors and lateral incisors were higher than those in thick gingival group,and the root length was smaller than thick gingival group.The difference was statistically significant(P＜0.05).The keratinized gingival width of thin gingival group was less than that of thick gingival group,and the difference was statistically significant(P＜0.05).Conclusion The relatively high crown-to-root ratio of mesial incisors and lateral incisors in patients with thin gingival phenotypes and the lesser width of keratinized gingiva in thin gingival phenotypes than thick gingival phenotypes.and risk assessment should be taken into account in the restorative system as well as in the orthodontic design of the anterior tooth movement.